1.850

-0.190 (-9.31%)
Range 1.620 - 2.010   (24.07%)
Open 2.010
Previous Close 2.040
Buy Price 1.800
Buy Volume 22
Sell Price 1.790
Sell Volume 14
Volume 10,553,128
Value -
Remark
Measurement Type Value
EPS (USD) -0.266
Trailing EPS (USD) -0.341
NAV (USD) 0.295
Cash In Hand (USD) 0.29
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 6.925
Price / Cash In Hand 7.047
Issued & Paid-up Shares 63,343,600
Treasury Shares 334
Market Cap (M) 129.221
Par Value (USD) n.a.
Beta - 75 Days 1.513
R-Squared - 75 Days(%) 0.94
Beta - 500 Days 0.386
R-Squared - 500 Days(%) 0.7
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 05 Mar 2021 05:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Earnings

Release Date 31 Mar 2021
View All Events

About CELSION CORPORATION

Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. As of December 31, 2011, the Company's product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer. ThermoDox is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a range of cancers. Localized heat at mild hyperthermia temperatures releases the encapsulated doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in and around the targeted tumor. In June 2014, it acquired all of the assets of EGEN Inc.

Loading Chart...